Dronabinol Is a Strong Contender for the First Sleep Apnea Pill
Dronabinol, synthetic THC, shows promise for the treatment of sleep apnea, and new advances from pharmaceutical companies suggest how it can be optimized.
Category: Emerging Compounds
Emerging Compounds
Latest
Emerging Compounds
Latest
Incannex’s IHL-42X Lowered AHI, ODI in Obstructive Sleep Apnea Phase 2 Trial
The clinical trial assessed three doses of IHL-42X at reducing the AHI in patients with OSA, as well as collected safety data.
Emerging Compounds
Latest
Incannex’s Drug Lowers AHI for Sleep Apnea Patients in Clinical Trial
The trial assessed 3 doses of Incannex Healthcare Ltd's cannabinoid combination product IHL-42X at reducing AHI in obstructive sleep apnea.
Sulthiame Lowers AHI At Least 50% in Trial
Sulthiame, a carbonic anhydrase inhibitor, lowered obstructive sleep apnea by more than 20 events/hour, a notable decline for a drug trial.
Read More
Sodium Oxybate Attributes: Does Once-Nightly Dosing Trump Low Sodium? Avadel Shares Its Findings
World Sleep 2022 attendees learned about results from an experiment about preferred attributes associated with oxybate treatments.
Read More
Proof-of-Concept Crossover Study of Two Sleep Apnea Pill Candidates Shows Promising Results
Topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, crossover study of sleep apnea pill candidates.
Read MoreAvadel Awaits FDA Decision on Once-Nightly Sodium Oxybate for Narcolepsy; Launch Prep Progressing
Avadel Pharmaceuticals plc recently provided a corporate update and announced its financial results for the third quarter ended September 30, 2021.
Read MoreAxsome Begins Phase 3 Trial for Narcolepsy Drug Candidate
The primary endpoint will be the frequency of cataplexy attacks. Other symptoms of narcolepsy as well as safety will also be assessed.
Read MoreREST-ON Trial Data, for Once-Nightly Sodium Oxybate, Published in Peer-Reviewed Journal
“We believe FT218 has tremendous potential to provide clinically meaningful results for people with narcolepsy.”
Read MoreHarmony Acquires Narcolepsy Drug Candidate with Novel Mechanism of Action
HBS-102 is a MCHR antagonist that has the potential to offer a novel approach to the treatment of narcolepsy including the symptoms of REM sleep dysregulation.
Read MoreFDA Grants Breakthrough Therapy Designation to Takeda’s Investigational Oral Orexin Agonist for Narcolepsy Type 1
The designation was based, in part, on early phase and preliminary clinical data that indicates Takeda’s investigational oral orexin agonist may demonstrate substantially improved objective and subjective measurements of daytime wakefulness in NT1 patients.
Read MoreIdorsia ‘Progressing Very Well’ with Prep for Anticipated Launch of Insomnia Drug Candidate
Allschwil, Switzerland-based Idorsia Ltd recently announced its financial results for the first half of 2021, at which time its drug daridorexant for the treatment of insomnia under review with United States FDA, EMA, and Swissmedic.
Read MoreSleep Specialist Becomes SVP, Medical Affairs at Sleep Apnea Pill Development Company Apnimed
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...
Read MoreKnock-Out Mouse Model Study Data Confirms Mazindol’s Orexin Pathway Activation for Treating Narcolepsy
The study demonstrated that knock out mice were 70% less sensitive to mazindol compared to normal mice, confirming mazindol’s potent activity as an OX2R agonist.
Read MoreAvadel Presents Data from Phase 3 Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy
“The new data analyses showing that FT218 improved excessive daytime sleepiness in patients with narcolepsy, both with and without cataplexy, regardless of stimulant use, are important for this patient population.”
Read More
Sleep Apnea Pill Data Presented at ATS 2021: ‘These Data Reinforce the Potential of Pharmacotherapy in Treating OSA’
The administration of reboxetine plus oxybutynin before bedtime greatly decreased OSA severity and increased next-day vigilance after 1 week.
Read More
Genes Reveal Secrets of Circadian Rhythm Sleep Disorders
In time, scientists’ growing understanding of the genetic underpinnings of delayed sleep phase and other circadian disorders could pave the way to novel therapeutics.
Read More
Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read More